Table 4 Comparison of opinions on aging and attitudes to PHT of women interested and non-interested in participating in a randomized PHT preventive trial in Estonia, proportion (%) of women, and age-adjusted odds-ratios (OR).1)
Interested | Non-interested | OR (95% CI) 2) | |
|---|---|---|---|
(n = 225) | (n = 553) | ||
% | % | ||
Menopause is a normal phase | 46 | 56 | 0.68 (0.50–0.94) |
Women do not loose femininity in menopause | 52 | 51 | 1.01 (0.73–1.39) |
PHT prevents osteoporosis | 27 | 9 | 4.27 (2.75–6.64) |
PHT should be given to all women with symptoms | 32 | 12 | 3.20 (2.16–4.74) |
PHT should be given to all postmenopausal women | 17 | 3 | 5.88 (3.18–10.88) |
Gave positive aspects of menopause | 20 | 17 | 1.38 (0.92–2.08) |
Gave negative aspects of menopause | 39 | 28 | 1.82 (1.30–2.57) |